A Randomized Trial of Pegylated Interferon α-2b Plus Ribavirin in the Retreatment of Chronic Hepatitis C

Jacobson, Ira M.; Gonzalez, Stevan A.; Ahmed, Furqaan; Lebovics, Edward; Min, Albert D.; Bodenheimer Jr., Henry C.; Esposito, Stephen P.; Brown Jr., Robert S.; Bräu, Norbert; Klion, Franklin M.; Tobias, Hillel; Bini, Edmund J.; Brodsky, Neil; Cerulli, Maurice A.; Aytaman, Ayse; Gardner, Peter W.; Geders, Jane M.; Spivack, Julie E.; Rahmin, Michael G.; Berman, David H.
November 2005
American Journal of Gastroenterology;Nov2005, Vol. 100 Issue 11, p2453
Academic Journal
OBJECTIVES: The efficacy of combination therapy with pegylated interferon (PEG IFN) α plus ribavirin (RBV) in the retreatment of chronic hepatitis C (CHC) in patients who previously failed combination standard IFN plus RBV or IFN monotherapy has not been well established. METHODS: Three hundred and twenty-one CHC patients including virologic nonresponders to combination IFN plus RBV (n = 219) or IFN monotherapy (n = 47), and relapsers to combination therapy (n = 55) were randomized to receive PEG IFN α-2b 1.5 μg/kg per wk plus RBV 800 mg per day (Regimen A, n = 160) or PEG IFN α-2b 1.0 μg/kg per wk plus RBV 1,000–1,200 mg per day (Regimen B, n = 161) for 48 wks. RESULTS: Sustained virologic response (SVR) occurred in 16% of the overall study population (Regimen A vs B, 18% vs 13%, p= 0.21), in 8% of the combination therapy nonresponders (10% vs 6%, p= 0.35), in 21% of the IFN monotherapy nonresponders (16% vs 27%, p= 0.35), and in 42% of the combination therapy relapsers (50% vs 32%, p= 0.18). In nonresponders to prior combination therapy, HCV ribonucleic acid levels <100,000 copies/mL at the end of the prior treatment course were associated with an increased SVR compared with levels ≥100,000 copies/mL (21% vs 5%, p= 0.002). In the overall study population, genotype 1 patients had lower SVR rates than others (14% vs 33%, p= 0.01), and African Americans had lower SVR than Caucasians (4% vs 18%, p= 0.01). CONCLUSION: Combination therapy with PEG IFN α-2b plus RBV is more effective in patients who relapsed after combination standard IFN plus RBV than in nonresponders to either combination therapy or IFN monotherapy. There was no significant effect of dosing regimen.


Related Articles

  • Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan. Kogure, Takayuki; Ueno, Yoshiyuki; Fukushima, Koji; Nagasaki, Futoshi; Kondo, Yasuteru; Inoue, Jun; Matsuda, Yasunori; Kakazu, Eiji; Yamamoto, Takeshi; Onodera, Hiroyoshi; Miyazaki, Yutaka; Okamoto, Hiromasa; Akahane, Takehiro; Kobayashi, Tomoo; Mano, Yutaka; Iwasaki, Takao; Ishii, Motoyasu; Shimosegawa, Tooru; Essaid, Abdellah; Rai, Ramesh Roop // World Journal of Gastroenterology;12/21/2008, Vol. 14 Issue 47, p7225 

    AIM: To evaluate the efficacy of pegylated interferon α-2b (peg-IFNα-2b) plus ribavirin (RBV) therapy in Japanese patients with chronic hepatitis C (CHC) genotype Ib and a high viral load. METHODS: One hundred and twenty CHC patients (58.3% male) who received peg-IFNα-2b plus RBV...

  • Tumor Necrosis Factor Receptor 1 Expression Is Upregulated in Dendritic Cells in Patients with Chronic HCV Who Respond to Therapy. Cubillas, Raul; Kintner, Katherine; Phillips, Frances; Karandikar, Nitin J.; Thiele, Dwain L.; Brown, Geri R. // Hepatitis Research & Treatment;2010, p1 

    The present studies assessed the level of tumor necrosis factor receptor (TNFR) expression in peripheral blood mononuclear cells (PBMCs) subsets from patients with chronic HCV undergoing interferon α/ribavirin-based therapy (Ifn/R). Methods. TNFR family member mRNA expression was determined...

  • Evolution of Interferon-Based Therapy for Chronic Hepatitis C. Chun-Hao Chen; Ming-Lung Yu // Hepatitis Research & Treatment;2010, p1 

    Since 1986, interferon-alfa (IFN-α) monotherapy has been administered for patients with chronic hepatitis C (CHC). However, sustained response rate is only about 8% to 9%. Subsequent introduction of ribavirin in combination with IFN-α was a major breakthrough in the treatment of CHC....

  • Interferon alpha-2a Plus Ribavirin 1,000/1,200 mg versus Interferon alpha-2a Plus Ribavirin 600 mg for Chronic Hepatitis C Infection in Patients on Opiate Maintenance Treatment: An Open-Label Randomized Multicenter Trial. Huber, M.; Weber, R.; Oppliger, R.; Vernazza, P.; Schmid, P.; Schönbucher, P.; Bertisch, B.; Meili, D.; Renner, E. // Infection;Feb2005, Vol. 33 Issue 1, p25 

    Background: Many intravenous opiate users are infected with hepatitis C virus (HCV) but few are treated. Although this complies with various guidelines, virtually no published evidence supports such a recommendation. Patients and Methods: In a multicenter study, HCV-infected patients in opiate...

  • Clinic Roundup.  // BioWorld Today;10/28/2013, Vol. 24 Issue 207, p8 

    The article focuses on several clinical trials conducted by various biotechnology and biopharmaceutical companies in 2013 including a trial of BIT225 in combination with pegylated interferon (IFN) and weight-based ribavirin (RBV) for the treatment of hepatitis C virus (HCV) and HIV conducted by...

  • Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C. Judit Morello; Sonia Rodríguez-Novoa; Inmaculada Jiménez-Nácher; Vincent Soriano // Journal of Antimicrobial Chemotherapy (JAC);Dec2008, Vol. 62 Issue 6, p1174 

    Ribavirin in combination with pegylated interferon α is the current standard treatment for chronic hepatitis C. Adequate exposure to ribavirin seems crucial for achieving the best virological response. However, anaemia is a frequent, dose-dependent limiting side effect of ribavirin use....

  • Kronik Hepatit C Hastalarının BeÅŸ Yıllık Tedavi Sonuçlarının DeÄŸerlendirilmesi. Akhan, Sıla; Aynıoğlu, Aynur; Sargın, Elif; Sayan, Murat // Klimik Journal / Klimik Dergisi;Aug2010, Vol. 23 Issue 2, p39 

    Objective: In this study, treatment results of patients with chronic hepatitis C (CHC) infected with hepatitis C virus (HCV) genotype 1 followed for five years were evaluated retrospectively. Methods: Between January 2004 and January 2010, 245 patients treated for CHC were evaluated. Of these,...

  • Four-week pegylated interferon α-2a monotherapy for chronic hepatitis C with genotype 2 and low viral load: A pilot, randomized study. Tsubota, Akihito; Satoh, Ken-ichi; Aizawa, Mashu; Takamatsu, Seishi; Namiki, Yoshihisa; Ohkusa, Toshifumi; Fujise, Kiyotaka; Tajiri, Hisao; Brady, Carla W. // World Journal of Gastroenterology;12/21/2008, Vol. 14 Issue 47, p7220 

    AIM: To assess the efficacy and advantages of 4-wk pegylated interferon α-2a (peg-IFN-α2a) monotherapy for chronic hepatitis C patients with strong predictors of sustained virologic response (SVR). METHODS: Patients (n = 33) with genotype 2 and low viral load (< 100 KIU/mL), who became HCV...

  • TREATMENT OF HEPATITIS C INFECTION: UNRAVELING THE MYSTERY. Monsour Jr., H. P. // American Journal of Gastroenterology;Sep1994, Vol. 89 Issue 9, p1424 

    Presents information on several studies on the treatment of hepatitis C with α-interferon 2b. Comparison of the amount of hepatitis C virus RNA in the serum between patients with chronic persistent hepatitis and patients with chronic active hepatitis or cirrhosis; Effectivity of interferon...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics